Samlyn Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Samlyn Capital’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-1,954,175	Closed	-$105M	–	135
2016 Q1	$105M	Buy	1,954,175 +305,662	+19%	+$17.9M	2.25%	8
2015 Q4	$108M	Sell	1,648,513 -882,487	-35%	-$54.5M	2.24%	14
2015 Q3	$143M	Buy	2,531,000 +398,840	+19%	+$25.9M	2.62%	6
2015 Q2	$126M	Buy	2,132,160 +310,760	+17%	+$19.2M	2%	11
2015 Q1	$113M	Buy	1,821,400 +123,900	+7%	+$7.2M	1.82%	18
2014 Q4	$97.6M	Buy	1,697,500 +630,800	+59%	+$35.1M	1.7%	17
2014 Q3	$57.3M	Buy	1,066,700 +296,700	+39%	+$15.7M	1.18%	42
2014 Q2	$40.4M	Buy	+770,000	New	+$39.4M	0.92%	51

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return

PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Samlyn Capital's TEVA Position: Q2 2016 in Review

Samlyn Capital sold out of Teva Pharmaceuticals (TEVA) in Q2 2016, closing a stake of 1,954,175 shares — an estimated $105M sold.

Samlyn Capital first reported a position in TEVA in Q2 2014 and held it in 8 quarters. The position peaked at $143M in Q3 2015. 813 funds tracked by Wall St. Rank hold TEVA as of Q2 2016.

Samlyn Capital reported no remaining Teva Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Samlyn Capital sold 1,954,175 Teva Pharmaceuticals shares in Q2 2016, an estimated $105M.
Samlyn Capital first reported a position in Teva Pharmaceuticals in Q2 2014 and held it in 8 quarters.
Samlyn Capital's Teva Pharmaceuticals position peaked at $143M in Q3 2015.
813 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2016.

Based on Samlyn Capital's 13F filing for Q2 2016, filed 15 Aug 2016.